A5023207351- Cervical Cancer and HPV Research
- Hepatitis B Virus Studies
- Genital Health and Disease
- Herpesvirus Infections and Treatments
- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Immunology Research
- Reproductive tract infections research
- vaccines and immunoinformatics approaches
- RNA regulation and disease
- Immunotherapy and Immune Responses
- T-cell and Retrovirus Studies
- Microbial infections and disease research
- SARS-CoV-2 detection and testing
University of Gothenburg
2022-2025
Karolinska Institutet
2019-2024
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2022
Significance Viral RNA may be edited by enzymes of the ADAR family that deaminate adenosine residues with ensuing A→G mutations. We found multiple mutations in minor viral populations SARS-CoV-2 genome. accumulated receptor binding domain spike gene, which cause structural changes altering to ACE2 receptor. Presence was associated reduced load, implying limit replication. Analyses >250,000 European samples from 2020 revealed were inversely correlated mortality as a reflection incidence....
Abstract Background Human papillomaviruses (HPV) cause several human cancers. Bivalent (Cervarix) and quadrivalent (qGardasil) HPV vaccines both contain virus-like particles of the major oncogenic types 16 18, but also cross-protect against some nonvaccine types. However, data on long-term sustainability cross-reactive antibody responses to are scarce. Methods Serum samples donated 7–12 years after immunization at age 16–17 with bivalent (n = 730) or 337) vaccine were retrieved from...
Human papillomavirus (HPV) vaccines protect against infections with the most oncogenic HPV types, cervical intraepithelial neoplasia (CIN) and cancer. We investigated whether development of lesions in HPV-vaccinated women is associated vaccine-targeted types or not. Linkage Swedish vaccination screening registries identified all females born 1980-2000 who had been vaccinated before December 31, 2014 (n = 305,320) attended 2006-2018 79,491). further selected below 17 years age screened...
Cervical cancer elimination through human papillomavirus (HPV) vaccination programs requires the attainment of herd effect. Due to its uniquely high basic reproduction number, coverage required achieve effect against HPV type 16 exceeds what is attainable in most populations. We have compared how gender-neutral and girls-only strategies create HPV16 under moderate achieved a population-based, community-randomized trial.
Solid organ transplant (SOT) recipients are at increased risk of Human Papillomavirus (HPV) persistent infection and disease. This study aimed to evaluate HPV seroprevalence, cervical prevalence, genotype distribution, frequency HPV-related lesions in SOT comparison immunocompetent women.Cross-sectional including women aged 18 45 years who denied previous lesions. Cervical samples were screened for HPV-DNA by a polymerase chain reaction (PCR)-based DNA microarray system (PapilloCheck®)...
Abstract Large scale human papillomavirus (HPV) vaccination against the most oncogenic high‐risk types 16/18 is rapidly reducing their incidence. However, attempts at assessing if this leads to an increase of nonvaccine targeted HPV have been hampered by several limitations, such as inability differentiate secular trends . We performed a population‐based serological survey unvaccinated young women over 12 years. The were under 23‐years‐old, residents from 33 communities which participated in...
Abstract Although HPV vaccines are highly efficacious, a notable proportion of quadrivalent vaccinees HPV18 seronegative post-vaccination. We have investigated this findings’ validity by comparing vaccine-induced antibody responses using two different immunoassays. 6558 16–17-year-old females participated in the FUTURE II (NCT00092534) and PATRICIA (NCT00122681) trials 2002–2004. Both bivalent vaccine recipients (QVR BVR) received three doses. Twelve-year follow-up for 648 was conducted...
Introduction Immunocompromised persons are at high risk of persistent Human Papilloma Virus (HPV) infection and associated diseases. Few studies evaluated HPV vaccines in immunocompromised persons. This study aimed to evaluate the quadrivalent vaccine (4vHPV) immunogenicity safety solid organ transplant (SOT) recipients, comparison immunocompetent women (IC). Methods Open-label clinical trial that enrolled SOT recipients aged 18 45 years. All participants received three doses 4vHPV vaccine....
Introduction The COVID-19 pandemic illustrates the need for serology diagnostics with improved accuracy. While conventional based on recognition of entire proteins or subunits thereof has made significant contribution to antibody assessment space, it often suffers from sub-optimal specificity. Epitope-based, high-precision, assays hold potential capture high specificity and diversity immune system, hence circumventing cross-reactivity closely related microbial antigens. Methods We herein...
Immunocompromised persons have high risk of persistent human papillomavirus (HPV) infection and HPV-related diseases, lower immune response to vaccines. This study evaluated the immunogenicity safety administering a fourth dose quadrivalent (4v)HPV vaccine in immunosuppressed women who did not seroconvert after three doses.
Pessoas imunocomprometidas apresentam alto risco de infecção persistente pelo Papiloma Vírus Humano (HPV) e cânceres associados. A melhor estratégia prevenção é a vacinação suscetíveis. Avaliar imunogenicidade segurança da vacina HPV quadrivalente (HPV4V) em transplantadas órgãos sólidos, comparação mulheres imunocompetentes mesma faixa etária. Ensaio clínico aberto, que foram incluídas 18 45 anos sólidos imunocompetentes. Todas as participantes receberam três doses (HPV4V, aos 0, 2 meses 6...